Evaluation of a breast mass

Overview

A palpable breast mass is any discrete lump a patient or clinician detects on breast tissue, most often a benign fibroadenoma or cyst but occasionally the first sign of invasive carcinoma. Evaluation is an algorithm, not a single test: age sets whether ultrasound or mammography comes first, and the resulting imaging category sets whether the mass is observed, re-imaged, or biopsied. It matters because breast cancer is the most common invasive malignancy in women, about 1 in 8 over a lifetime, and the second most common cause of cancer death after lung cancer, while most masses under 30 are benign. Treatment follows triage: history and clinical breast exam, age-stratified imaging, then tissue sampling whenever findings are discordant or suspicious.

Epidemiology

Most palpable breast masses are benign, particularly under age 30, where cysts, fibroadenomas, fat necrosis, and lipomas predominate because dense glandular tissue in this age group more often produces a benign lump. Fibroadenoma is the most common breast mass in adolescents and young women, peaking between ages 15 and 35. A new mass in a postmenopausal woman carries far higher pretest probability of cancer, with a median age at breast cancer diagnosis around 62 years. Male breast masses are gynecomastia far more often than cancer, but a firm, eccentric, unilateral mass in a man older than 50 needs the same biopsy threshold as in a woman.

Risk factors

• Age: a malignant mass becomes more likely after age 40 and again after menopause.
• Family and personal history: a first-degree relative with breast cancer, a personal history of it, or a prior biopsy showing atypical hyperplasia each make a new mass more likely to be malignant.
• Inherited mutation: carriers of a mutation in the breast cancer susceptibility gene 1 or 2 (BRCA1 or BRCA2), DNA-repair tumor suppressors, develop cancer earlier and warrant earlier biopsy rather than observation.
• Hormonal exposure: early menarche, late menopause, nulliparity, first pregnancy after age 30, and hormone therapy each shift a mass toward malignant on the differential.
• Breast density: dense tissue limits mammographic sensitivity, why ultrasound is favored under age 30.
• Trauma or lactation: blunt trauma or surgery predisposes to fat necrosis; breastfeeding predisposes to galactocele and mastitis.
• Male risk factors: Klinefelter syndrome and BRCA2 mutation make a male mass more likely malignant rather than gynecomastia.

Pathophysiology

Benign and malignant masses arise from different compartments of the breast. Fibroadenoma is a hormonally responsive proliferation of epithelial and stromal elements that grows with estrogen exposure such as pregnancy and shrinks after menopause. A simple cyst is a fluid-filled dilation of a terminal duct, benign unless the fluid is bloody. Fat necrosis follows saponification of adipocytes after blunt injury, calcifying on imaging in a way that can mimic malignancy. Phyllodes tumor is a fibroepithelial neoplasm with stromal overgrowth and leaf-like projections that outgrows fibroadenoma. Malignant transformation follows ductal hyperproliferation through atypical hyperplasia and carcinoma in situ to invasive carcinoma once cells breach the basement membrane; germline BRCA1 or BRCA2 mutations impair DNA repair and accelerate this sequence. An invasive tumor fixed to Cooper ligaments and dermal lymphatics produces the dimpling and peau d'orange edema of advanced malignancy.

Clinical features

• Benign contour: mobile, well-circumscribed, smooth or rubbery, often tender or fluctuating with the cycle, typical of fibroadenoma or fibrocystic change.
• Malignant contour: firm to hard, fixed, immobile, ill-defined margins, usually painless, most often upper outer quadrant.
• Time course: fibroadenoma is stable over months to years; a mass enlarging over weeks favors phyllodes tumor or carcinoma; fever and warmth over days favors mastitis.
• Skin and nipple changes: dimpling, retraction, peau d'orange edema, or an eczematous nipple rash point toward advanced or inflammatory malignancy.
• Nodal findings: axillary or supraclavicular lymphadenopathy with a mass points toward malignant spread.
• Nipple discharge: unilateral, spontaneous, serous, or bloody discharge, especially with a subareolar mass, gets the same workup as a palpable mass.
• Limited exam accuracy: a smooth, mobile mass suggests benign disease and a fixed, hard mass suggests malignancy, but exam alone never confirms either.

Differential diagnosis

• Fibroadenoma: round, well-circumscribed, rubbery, mobile, uniformly hypoechoic on ultrasound, unchanged by the cycle, unlike the fixed, irregular mass of carcinoma.
• Simple breast cyst: anechoic with posterior acoustic enhancement, disappearing completely with clear fluid on aspiration, unlike a solid mass that persists.
• Fibrocystic change: bilateral, multifocal nodularity and cyclical pain fluctuating with the cycle, unlike a persistent, unilateral, dominant mass.
• Fat necrosis: a firm mass after blunt trauma or surgery, though half of patients recall none, with a calcified oil cyst on mammography rather than a spiculated carcinoma.
• Phyllodes tumor: presents like fibroadenoma but grows quickly with leaf-like papillary stromal projections on histology, unlike stable fibroadenoma.
• Intraductal papilloma: unilateral, serous, or bloody nipple discharge with a subareolar mass in a nonlactating woman, unlike fibroadenoma, which rarely discharges.
• Lactational mastitis or abscess: a warm, erythematous, tender breast with fever in a breastfeeding patient responding to antibiotics within 48 to 72 hours, unlike inflammatory breast cancer, which does not.
• Inflammatory breast cancer: diffuse erythema, warmth, and peau d'orange without a discrete mass, fails to respond to antibiotics, and is distinguished from mastitis by skin punch biopsy.
• Invasive carcinoma: a hard, fixed, painless mass with ill-defined margins, often with skin or nipple retraction, unlike the mobile, well-circumscribed lesions above.

Diagnosis

• First, diagnosis is established by concordance between exam, imaging, and tissue sampling: core needle biopsy confirms or excludes malignancy whenever a mass is clinically suspicious, growing, or imaging-discordant, regardless of a reassuring imaging category.
• Then obtain a focused history and clinical breast exam, with inspection for skin or nipple change and palpation of the breast, axilla, and supraclavicular fossa.
• If nipple discharge accompanies the mass, obtain a pregnancy test with prolactin and thyroid-stimulating hormone before imaging to exclude a nonbreast cause.
• Next, obtain age-stratified imaging: ultrasound alone under age 30, or mammography plus targeted ultrasound at 30 or older or in a man of any age; imaging always precedes biopsy since biopsy distorts tissue.
• Findings are scored with the Breast Imaging Reporting and Data System (BI-RADS): category 1 to 2 is negative or benign, category 3 carries under 2% risk and gets repeat imaging at 6 to 12 month intervals for 2 years, category 4 (4A 2% to 10%, 4B 10% to 50%, 4C 50% to 95%) and category 5 (95% or greater) warrant biopsy, and category 6 is already biopsy-proven.
• If a mass feels cystic, fine needle aspiration both diagnoses and treats it: clear fluid with complete collapse gets exam at 6 weeks, while bloody fluid or recurrence twice within 4 to 6 weeks escalates to core biopsy.
• Once imaging shows a solid or category 4 to 5 lesion, core needle biopsy is preferred over aspiration for histologic subtyping; excisional biopsy is reserved for a discordant result.

Clinical pearl. Any clinically suspicious mass, fixed and hard on exam, still requires biopsy even when mammography and ultrasound report a reassuring BI-RADS 1 or 2, because imaging can be falsely reassuring and clinical suspicion overrides a discordant result.

Management

• First, triage disposition by BI-RADS category and clinical suspicion, not presumed diagnosis alone. Category 1 or 2 returns to routine screening; category 3 gets repeat imaging at 6 to 12 month intervals; category 4 or 5, or any clinically suspicious exam, goes to core needle biopsy and referral to a breast surgeon.
• If aspiration confirms a simple cyst that disappears completely, the 6-week recheck is all that follows; a complex or bloody cyst is biopsied as a solid lesion.
• If biopsy confirms fibroadenoma, follow with annual exam and imaging; refer for excision if the mass exceeds 3 cm, causes discomfort, or grows.
• If the mass is a warm, tender, febrile breast in a lactating patient, treat presumed lactational mastitis with an oral antistaphylococcal antibiotic while continuing breastfeeding or pumping:
  • Dicloxacillin 500 mg PO four times daily for 10 to 14 days, first-line without penicillin allergy.
  • Cephalexin 500 mg PO four times daily for 10 to 14 days, an equivalent alternative.
  • Clindamycin 300 mg PO four times daily for 10 to 14 days if penicillin-allergic or methicillin-resistant Staphylococcus aureus is suspected.
• If mastitis has not responded within 48 to 72 hours, obtain breast ultrasonography for abscess; drain a confirmed abscess and send fluid or tissue for culture and histology to exclude inflammatory breast cancer.
• If core biopsy confirms invasive carcinoma or ductal carcinoma in situ, refer to a breast surgeon for staging and treatment planning.
• If pathology and imaging are discordant, or core biopsy shows atypical hyperplasia, proceed to excisional biopsy rather than accept the core result as final.

Complications

• Missed or delayed cancer diagnosis: occurs when a suspicious mass is observed instead of biopsied because imaging was reassuring, or a category 3 finding grows between intervals without repeat sampling.
• Biopsy-imaging discordance: a benign result that does not match a suspicious imaging appearance needs repeat or excisional biopsy, since a first sample can miss the abnormal focus.
• Progression to abscess: inadequately treated lactational mastitis can progress to a drainable abscess within days.
• Biopsy-related bleeding or infection: core needle and excisional biopsy carry a small risk of hematoma or wound infection.
• Upgrade on excision: atypical hyperplasia on core biopsy is occasionally upgraded to cancer on the larger specimen.

Prognosis

Most palpable breast masses are benign with an excellent prognosis once correctly identified; fibroadenoma, simple cyst, fat necrosis, and fibrocystic change do not shorten life expectancy. Prognosis for a malignant mass tracks stage at diagnosis, why the age-stratified algorithm exists: prompt evaluation finds cancer at an earlier, more favorable stage than delayed diagnosis does. Inflammatory breast cancer, the mimic most often confused with mastitis, carries a poor prognosis, about 50% survival at 5 years, why a failure to respond within 48 to 72 hours must trigger biopsy, not a second antibiotic course. Phyllodes tumor recurs locally with inadequate margins but rarely metastasizes when benign on histology.

Prevention

• Average-risk screening: mammography every 1 to 2 years beginning between ages 40 and 50, per major guideline bodies, distinct from evaluating a new symptomatic mass, which is imaged at any age.
• Clinical breast exam is not a screening tool: clinicians should not use it alone to screen asymptomatic women, though it stays part of the workup once a patient reports a mass.
• High-risk surveillance: a BRCA1 or BRCA2 mutation, an untested first-degree relative of a carrier, or prior chest irradiation between ages 10 and 30 warrants earlier imaging, including annual breast MRI.
• Adherence to interval follow-up: since a BI-RADS 3 finding still carries up to 2% malignancy risk, keeping the 6 to 12 month re-imaging schedule for 2 years keeps a slow-growing malignancy from being lost.

Key points

• Age drives the first imaging choice: ultrasound alone under 30, mammography plus ultrasound at 30 or older, in both sexes.
• BI-RADS category, not gestalt, drives disposition: category 1 to 2 observe, category 3 short-interval follow-up, category 4 to 5 biopsy.
• Clinical suspicion overrides reassuring imaging: a fixed, hard mass still needs biopsy even after a BI-RADS 1 or 2 result.
• Imaging always precedes biopsy because biopsy distorts tissue architecture.
• The most common evaluation error is treating inflammatory breast cancer as mastitis; a failure to respond within 48 to 72 hours is the trigger to biopsy, not another antibiotic course.
• A postmenopausal mass is cancer until proven otherwise, while most masses under 30 are benign, so pretest probability differs sharply by age. </content>